Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $756,000.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 36,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $21.00, for a total transaction of $756,000.00. Following the completion of the transaction, the chief financial officer directly owned 118,842 shares in the company, valued at approximately $2,495,682. This represents a 23.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

CeriBell Stock Up 1.0%

Shares of CeriBell stock opened at $21.93 on Thursday. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $26.83. The stock has a market cap of $813.60 million, a price-to-earnings ratio of -14.52 and a beta of 1.35. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The company has a fifty day moving average price of $16.64 and a 200 day moving average price of $14.88.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. Equities research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CBLL. TD Cowen lowered their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Raymond James Financial initiated coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Monday, December 15th. Canaccord Genuity Group upped their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.67.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CBLL. Geode Capital Management LLC increased its position in shares of CeriBell by 55.4% in the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after purchasing an additional 159,698 shares during the last quarter. Squarepoint Ops LLC bought a new stake in CeriBell in the second quarter valued at about $1,054,000. Police & Firemen s Retirement System of New Jersey raised its stake in CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares in the last quarter. F m Investments LLC bought a new position in CeriBell during the 2nd quarter worth approximately $381,000. Finally, TimesSquare Capital Management LLC grew its position in shares of CeriBell by 48.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after acquiring an additional 260,116 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.